2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting ...Middle East

SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to...

Read More Details
Finally We wish PressBee provided you with enough information of ( 2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting )

Also on site :

• Matthew Goode Explains Absence From ‘Downton Abbey 3’: “Maybe It’s A Good Thing”
• ‘America is not for sale:’ Protesters mob Trump golf course guests ahead of exclusive crypto dinner
• Ukraine-Russia war latest: Major Moscow airports shut after Kyiv’s overnight drone strikes